Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Shih

Showing results (571-580 of 659) with videos related to

Pageof 66
Sort By:
Leukemia|December 25, 2004
CEBPalpha mutations in childhood acute myeloid leukemiaD-C Liang, L-Y Shih, C-F Huang, et al.
Brain Communications|February 16, 2022
Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapyLila D Faulhaber, Anthea Q Phuong, Kendra Jae Hartsuyker, et al.
Nature Neuroscience|February 19, 2021
Brain capillary pericytes exert a substantial but slow influence on blood flowDavid A Hartmann, Andrée-Anne Berthiaume, Roger I Grant, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivoN Y Shih, R Aslanian, A T Lupo, et al.
Molecular Cell|December 6, 2024
Reactive oxygen species control protein degradation at the mitochondrial import gateRachael McMinimy, Andrew G Manford, Christine L Gee, et al.
Science (New York, N.Y.)|July 15, 1988
Congenital poisoning by polychlorinated biphenyls and their contaminants in TaiwanW J Rogan, B C Gladen, K L Hung, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2023
pH Dependence of a GPR4 Selective Antagonist Hampers Its Therapeutic PotentialJacek Stalewski, Amy Y Shih, Romeo Papazyan, et al.
Journal of Virology|July 1, 1980
Functional organization of the Harvey murine sarcoma virus genomeE H Chang, J M Maryak, C M Wei, et al.
Arzneimittel-Forschung|October 30, 1998
Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971J A Hey, R Aslanian, D C Bolser, et al.
ESMO Open|September 24, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter studyP Schöffski, A Gazzah, J Trigo, et al.
Pageof 66

Showing results (571-580 of 659) with videos related to

Sort By:
Pageof 66
Leukemia|December 25, 2004
CEBPalpha mutations in childhood acute myeloid leukemiaD-C Liang, L-Y Shih, C-F Huang, et al.
Brain Communications|February 16, 2022
Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapyLila D Faulhaber, Anthea Q Phuong, Kendra Jae Hartsuyker, et al.
Nature Neuroscience|February 19, 2021
Brain capillary pericytes exert a substantial but slow influence on blood flowDavid A Hartmann, Andrée-Anne Berthiaume, Roger I Grant, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivoN Y Shih, R Aslanian, A T Lupo, et al.
Molecular Cell|December 6, 2024
Reactive oxygen species control protein degradation at the mitochondrial import gateRachael McMinimy, Andrew G Manford, Christine L Gee, et al.
Science (New York, N.Y.)|July 15, 1988
Congenital poisoning by polychlorinated biphenyls and their contaminants in TaiwanW J Rogan, B C Gladen, K L Hung, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 4, 2023
pH Dependence of a GPR4 Selective Antagonist Hampers Its Therapeutic PotentialJacek Stalewski, Amy Y Shih, Romeo Papazyan, et al.
Journal of Virology|July 1, 1980
Functional organization of the Harvey murine sarcoma virus genomeE H Chang, J M Maryak, C M Wei, et al.
Arzneimittel-Forschung|October 30, 1998
Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971J A Hey, R Aslanian, D C Bolser, et al.
ESMO Open|September 24, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter studyP Schöffski, A Gazzah, J Trigo, et al.
Pageof 66